Abstract

The purpose of the present study is to perform a clinical validation of a new commercial Monte Carlo (MC) based treatment planning system (TPS) for electron beams, i.e. the XiO 4.60 electron MC (XiO eMC). Firstly, MC models for electron beams (4, 8, 12 and 18 MeV) have been simulated using BEAMnrc user code and validated by measurements in a homogeneous water phantom. Secondly, these BEAMnrc models have been set as the reference tool to evaluate the ability of XiO eMC to reproduce dose perturbations in the heterogeneous phantom. In the homogeneous phantom calculations, differences between MC computations (BEAMnrc, XiO eMC) and measurements are less than 2% in the homogeneous dose regions and less than 1 mm shifting in the high dose gradient regions. As for the heterogeneous phantom, the accuracy of XiO eMC has been benchmarked with predicted BEAMnrc models. In the lung tissue, the overall agreement between the two schemes lies under 2.5% for the most tested dose distributions at 8, 12 and 18 MeV and is better than the 4 MeV one. In the non-lung tissue, a good agreement has been found between BEAMnrc simulation and XiO eMC computation for 8, 12 and 18 MeV. Results are worse in the case of 4 MeV calculations (discrepancies ≈ 4%). XiO eMC can predict dose perturbation induced by high-density heterogeneities for 8, 12 and 18 MeV. However, significant deviations found in the case of 4 MeV demonstrate that caution is necessary in using XiO eMC at lower electron energies.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call